Real-world treatment patterns, healthcare resource utilization and total cost of care in mantle cell lymphoma from US commercial claims

Aim: To describe treatment patterns and economic burden in patients with mantle cell lymphoma (MCL). Patients & methods: A retrospective cohort study of adults with MCL utilizing commercial claims (2015–2021) was conducted. Results: The most common regimens were bendamustine plus rituximab-based (28.5%) and rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)/CHOP-based (17.6%) in first-line (1L), hematopoietic stem cell transplantation (HSCT) in second-line (2L; 23.9%) and rituximab in third-line (3L; 43.7%) treatment. Respective to 1L, 2L and 3L, approximately 9.6%, 14.0% and 19.8% of patients received Bruton tyrosine kinase inhibitors, and mean total healthcare costs were $262,529, $365,892 and $260,744 per patient per year. Conclusion: Patients with MCL received guideline-concordant therapies and incurred substantial healthcare resource utilization and costs.